The Week in Review: September 15 – September 22, 2017

Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad).  Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...

Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

– New Data for First Approved Pan-genotypic Once-Daily Single Tablet Regimen for  Chronic Hepatitis C Virus Infection – MISSISSAUGA, ON, Sept. 21, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for updated labeling of EPCLUSA® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults w...

The Financial Burden of Liver Disease

Liver disease is a common cause of premature death in the UK. Recently, The Lancet Commission on Liver Disease highlighted the financial impact liver disease places on the national healthcare system and businesses, and suggested strategies to reduce these burdens. The negative impacts of liver disease on citizens under the age of 65 in the UK are escalating, particularly in those from low socioeconomic backgrounds. This can be reversed by targeting the th

In HBV, high core-related antigen levels predict cirrhosis

Elevated hepatitis B virus core-related antigen levels significantly increased the risk for progression to cirrhosis among patients with chronic hepatitis B who are hepatitis B e antigen-negative and are not receiving nucleos(t)ide analogue therapy, according to recently published data. “Recently, various indices of liver fibrosis based on clinical and biological data have been reported to be useful predictors of fibrosis in liver disease,” Toshifumi Tada

Malaysia Allows Generics for Gilead’s Hepatitis C Drug for Which India Issued Patent

The Malaysian government has approved a government-use compulsory license which would allow the import of generic versions of Gilead’s patented hepatitis C drug, Sovaldi. The decision was made in August but has become public this week. On September 14, the Malaysian cabinet approved for this license. The move will make generic and cheaper versions of the same drug, which has been sold globally at $1000 per pill. The low-cost versions will now be available

Restrictions Lifted: All Swiss hepatitis C sufferers can access costly drugs like Harvoni

All patients suffering from hepatitis C can be treated with the drugs Harvoni and Epclusa from next month, after the Federal Office of Public Health lifted restrictions allowing the medicines to be reimbursed by mandatory health insurance. The two drugs will be available to all patients irrespective of the level and stage of infection, the office said in a statement on Tuesday. The brand-name drugs (sold as Harvoni or Epclusa) manufactured by American pha